Common polymorphisms influencing serum uric acid levels contribute to susceptibility to gout, but not to coronary artery disease

PLoS ONE

Volumn 4, Issue 11, 2009, Pages

  Stark, Klaus ^a   Reinhard, Wibke ^a   Grassl, Martina ^a   Erdmann, Jeanette ^b   Schunkert, Heribert ^b   Illig, Thomas ^c   Hengstenberg, Christian ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c Institute of Epidemiology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGOUT AGENT; ANTILIPEMIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; DIURETIC AGENT; GENE PRODUCT; PROTEIN GCKR; PROTEIN LRRC16A; PROTEIN PDZK1; PROTEIN SLC16A9; PROTEIN SLC22A11; PROTEIN SLC22A12; PROTEIN SLC2A9; SODIUM PHOSPHATE COTRANSPORTER 1; SODIUM PHOSPHATE COTRANSPORTER 3; UNCLASSIFIED DRUG; URIC ACID; URICOSURIC AGENT; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; GLUCOSE TRANSPORTER; SLC2A9 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; GENOTYPE; GOUT; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; QUANTITATIVE TRAIT; SINGLE NUCLEOTIDE POLYMORPHISM; URIC ACID BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ATP-BINDING CASSETTE TRANSPORTERS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GOUT; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; URIC ACID;

EID: 70450159659     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007729     Document Type: Article

References (32)

1. Campion EW, Glynn RJ, deLabry LO (1987) Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 82: 421-426.
2. Li S, Sanna S, Maschio A, Busonero F, Usala G, et al. (2007) The GLUT9 Gene Is Associated with Serum Uric Acid Levels in Sardinia and Chianti Cohorts. PLoS Genet 3: e194.
3. Stark K, Reinhard W, Neureuther K, Wiedmann S, Sedlacek K, et al. (2008) Association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in a large case-control study. PLoS ONE 3: e1948.
4. Döring A, Gieger C, Mehta D, Gohlke H, Prokisch H, et al. (2008) SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 40: 430-436.
5. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, et al. (2008) SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 40: 437-442.
6. Dehghan A, Kottgen A, Yang Q, Hwang SJ, Kao WL, et al. (2008) Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 372: 1953-1961.
7. Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, et al. (2009) Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 5: e1000504.
8. Culleton BF, Larson MG, Kannel WB, Levy D (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 131: 7-13.
9. Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 283: 2404-2410.
10. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, et al. (2004) Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 164: 1546-1551.
11. Erdmann J, Grosshennig A, Braund PS, König IR, Hengstenberg C, et al. (2009) New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet 41: 280-282.
12. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, et al. (2007) Genomewide association analysis of coronary artery disease. N Engl J Med 357: 443-453.
13. Devlin B, Roeder K (1999) Genomic control for association studies. Biometrics 55: 997-1004.
14. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
15. Faul F, Erdfelder E, Lang AG, Buchner A (2007) G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39: 175-191.
16. Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, et al. (2008) Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 283: 26834-26838.
17. Caulfield MJ, Munroe PB, O'Neill D, Witkowska K, Charchar FJ, et al. (2008) SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 5: e197.
18. Matsuo H, Chiba T, Nagamori S, Nakayama A, Domoto H, et al. (2008) Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 83: 744-751.
19. Lee WC (2003) Searching for disease-susceptibility loci by testing for Hardy-Weinberg disequilibrium in a gene bank of affected individuals. Am J Epidemiol 158: 397-400.
20. Xu J, Turner A, Little J, Bleecker ER, Meyers DA (2002) Positive results in association studies are associated with departure from Hardy-Weinberg equilibrium: hint for genotyping error? Hum Genet 111: 573-574.
21. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, et al. (2007) Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis (2007): DOI:10.1136/ ard.2007.076232.
22. Mandell BF (2008) Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med 75 Suppl 5: S5-S8.
23. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, et al. (2002) Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417: 447-452.
24. Abbott RD, Brand FN, Kannel WB, Castelli WP (1988) Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol 41: 237-242.
25. Baker JF, Krishnan E, Chen L, Schumacher HR (2005) Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 118: 816-826.
26. Choi HK, Curhan G (2007) Independent impact of gout on mortality and risk for coronary heart disease. Circulation 116: 894-900.
27. Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, et al. (2004) Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health 4: 9.
28. Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359: 1811-1821.
29. Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-678.
30. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, et al. (2007) A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316: 1491-1493.
31. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, et al. (2007) A common allele on chromosome 9 associated with coronary heart disease. Science 316: 1488-1491.
32. Tregouet DA, König IR, Erdmann J, Munteanu A, Braund PS, et al. (2009) Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 41: 283-285.